We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    SodiUm SeleniTe Administration IN Cardiac Surgery
Previous Study | Return to List | Next Study

SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial). (SUSTAINCSX)

This study is currently recruiting participants.
Verified October 2017 by Daren K. Heyland, Clinical Evaluation Research Unit at Kingston General Hospital
Sponsor:
ClinicalTrials.gov Identifier:
NCT02002247
First Posted: December 5, 2013
Last Update Posted: October 3, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
biosyn Arzneimittel GmbH
Queen's University
RWTH Aachen University
Information provided by (Responsible Party):
Daren K. Heyland, Clinical Evaluation Research Unit at Kingston General Hospital
  Purpose
The aim of the investigators' research program is to investigate the effects of perioperative high dose selenium supplementation in high-risk cardiac surgical patients undergoing complicated open heart surgery. The investigators hypothesize that the therapeutic strategy tested in this randomized trial may contribute to a fewer complications, less organ injury and fewer deaths. Before the investigators conducted the large definitive trial, they conducted a pilot study to assess the feasibility of the protocol, and are rolling the pilot patients into the definitive trial.

Condition Intervention Phase
Heart Disease Drug: sodium selenite Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial). A Multicentre Randomized Controlled Trial of High Dose Sodium-selenite Administration in High Risk Cardiac Surgical Patients

Resource links provided by NLM:


Further study details as provided by Daren K. Heyland, Clinical Evaluation Research Unit at Kingston General Hospital:

Primary Outcome Measures:
  • PODS free days + alive [ Time Frame: 30 Day ]
    Evaluate the PODS free days + alive as the primary outcome for the large-scale Phase III trial. We define PODS as the need for life-sustaining therapies (mechanical ventilation, vasopressor therapy, mechanical circulatory support, continuous renal replacement therapy, or intermittent hemodialysis).


Secondary Outcome Measures:
  • 30-Day Mortality [ Time Frame: 30 Day ]
    Mortality 30 days post-randomization.

  • Hospital Acquired Infections [ Time Frame: 30 day ]
    To be evaluated up to 6 months post-randomization.

  • Perioperative hemodynamic profile [ Time Frame: 6 months ]
    This includes: mean arterial blood pressure, cardiac power index, systemic vascular resistance, etc... To be assessed up to 6-months post-randomization.

  • Cardiovascular Complications [ Time Frame: 6-months ]
    This includes: arrhythmias, cardiac arrest, infarction. To be assessed up to 6-months.

  • Duration of Mechanical Ventilation [ Time Frame: 6-months ]
    To be assessed up to 6-months.

  • Incidence of post-operative delirium [ Time Frame: 6-months ]
    Assessed by CAM-ICU score. To be assessed up to 6-months.

  • ICU Length of stay [ Time Frame: 6-months ]
    To be assessed up to 6 months post-randomization.

  • Hospital Re-admission Rates [ Time Frame: 6-months ]
    To be assessed up to 6-months post-randomization.

  • Hospital Length of stay [ Time Frame: 6-months ]
    To be assessed up to 6 months post-randomization.

  • 6-Month Survival [ Time Frame: 6-months ]
    To be assessed at 6 months post-randomization.

  • Quality of Life [ Time Frame: 6-months ]
    Health related quality of life to be assessed up to 6-months post-randomization.

  • Return to work [ Time Frame: 6-months ]
    Assessed using a questionnaire to determine the patient's ability to return to their pre-operative working capabilities. To be assessed up to 6 months post-randomization.


Other Outcome Measures:
  • Laboratory outcomes [ Time Frame: POD 10 ]

    To be assessed up to post-operative day (POD) 10 in patients who consent to this optional blood work.

    To assess the potential effects of supplementation on selenium levels, safety parameters and other mechanistic markers. Whole blood levels of selenium, selenoprotein P (Sel-P), antibodies against oxidized LDL, markers of inflammation (interleukin[IL]-6, IL-10, TNF alpha) and activity of glutathione-peroxidase (GPx) will be assessed to determine the efficacy of selenium supplementation in these patients.



Estimated Enrollment: 1400
Study Start Date: January 2015
Estimated Study Completion Date: June 2020
Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Normal saline will be administered to subjects intravenously pre-operatively, upon admission to the ICU, then daily up to post-operative day 10 or ICU discharge, whichever occurs first.
Drug: Placebo
All patients will receive an IV bolus of normal saline (equals to 40ml prepared solution) within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of normal saline accordingly. Then on every further morning during ICU-stay, patients will receive an IV bolus of normal saline via central or peripheral venous access until death, discharge from ICU to the ward (treatment may continue in a step down or intermediate care unit), or for a maximum of 10 days.
Other Name: NaCl 0.9%
Active Comparator: sodium selenite

High-dose sodium-selenite will be administered to subjects intravenously:

1) pre-operatively (2000 ug); 2) upon admission to the ICU (2000 ug), 3) then daily (1000 ug) up to post-operative day 10 or ICU discharge, whichever occurs first.

Drug: sodium selenite
All subjects will receive an IV bolus of 2000µg selenium within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of 2000µg selenium. Then on every further morning during ICU-stay, patients will receive an IV bolus of 1000µg selenium via central or peripheral venous access until death, discharge from ICU to the ward, or for a maximum of 10 days.
Other Name: selenium

Detailed Description:

Over a million patients undergo open heart surgery annually and this number is likely to accelerate as the population ages and the prevalence of diabetes and cardiovascular disease continue to increase. Unfortunately, death, organ failure, and other serious complications are all too frequent following open heart surgery, especially in some high-risk patient populations.

Selenium is a trace element that is important for many of the body's regulatory and metabolic functions especially during times of stress. International members of the study team have shown in a non-randomized study that high dose selenium supplementation was associated with improved clinical outcomes compared to a historical control group. The next step in this program of research is to conduct a randomized trial.

The aim of this research program is to investigate the effects of perioperative high dose selenium supplementation in high-risk cardiac surgical patients undergoing complicated open heart surgery. The investigators hypothesize that the therapeutic strategy tested in this randomized trial may contribute to fewer complications, less organ injury and fewer deaths.

The investigators propose to conduct a randomized, placebo-controlled, double-blind, multicentre definitive trial of 1400 patients across 20 sites in Germany and Canada, which will include the pilot study patients. An industry partner (Biosyn) will provide the product and some additional support for the European sites. Patients will be randomized to receive either a daily perioperative high-dose selenium or placebo until postoperative day 10 (maximum) or upon earlier discharge from ICU. If the hypothesis is proven true, and this simple, inexpensive nutrient reduces complications and improves recovery of patients undergoing cardiac surgery, there is the potential to dramatically change clinical practice and improve health outcomes.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients (>18 years of age)
  • Scheduled to undergo elective or urgent cardiac surgery with the use of cardiopulmonary bypass (CPB) and cardioplegic arrest that exhibit a high perioperative risk profile as defined by the presence of one or more of the following:

    • a) Planned valve surgery combined with CABG or multiple valve replacement/repair surgeries or combined cardiac surgical procedures involving the thoracic aorta;
    • b) Any cardiac surgery with a high perioperative risk profile, defined as a predicted operative mortality of ≥ 5% (EuroSCORE II).

Exclusion Criteria:

We will exclude patients who meet any of the following criteria:

  • Known hypersensitivity to sodium-selenite or to any of the constituents of the solution.
  • Renal failure requiring dialysis at the point of screening.
  • Chronic liver disease as evidenced by a pre-operative total bilirubin >2 mg/dl or 34 umol/L.
  • Disabling neuropsychiatric disorders (severe dementia, severe Alzheimer's disease, advanced Parkinson's disease).
  • Pregnancy or lactation period.
  • Simultaneous participation in another clinical trial of an experimental therapy (co-enrolment acceptable in observational studies or randomized trials of existing therapies if permitted by both steering committees and local ethics boards).
  • Patients undergoing heart transplantation or preoperative planned LVAD insertion or complex congenital heart surgery.
  • Family members of investigators (required by German Regulatory Authorities).
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02002247


Contacts
Contact: Daren K Heyland, MD 613-549-6666 ext 4847 dkh2@queensu.ca

Locations
Canada, Ontario
Hamilton General Hospital Recruiting
Hamilton, Ontario, Canada
Contact: Whitlock Richard, MD         
London Health Sciences Centre Recruiting
London, Ontario, Canada
Contact: Phil Jones, MD         
University of Ottawa Heart Institute Recruiting
Ottawa, Ontario, Canada
Contact: Bernard J McDonald, MD         
Principal Investigator: Bernard J McDonald, MD         
Sunnybrook Health Sciences Centre Recruiting
Toronto, Ontario, Canada, M4N3M5
Principal Investigator: Stephen Fremes, MD         
Principal Investigator: Robert Fowler, MD         
St. Michael's Hospital Recruiting
Toronto, Ontario, Canada
Contact: David Mazer, MD         
Toronto General Hospital Not yet recruiting
Toronto, Ontario, Canada
Contact: Matteo Parotto, MD         
Canada, Quebec
Institut de cardiologie de Montreal Recruiting
Montreal, Quebec, Canada, H1C1T8
Contact: Yoan Lamarche, MD         
Principal Investigator: Yoan Lamarche, MD         
McGill University Health Centre Recruiting
Montreal, Quebec, Canada
Contact: Roupen Hatzakorzian, MD         
Sacre Coeur Recruiting
Montreal, Quebec, Canada
Contact: Yoan Lamarche, MD         
IUCPQ Recruiting
Quebec City, Quebec, Canada
Contact: Siamak Mohammadi, MD         
Germany
RWTH Aachen University Hospital Recruiting
Aachen, Germany, 52074
Contact: Christian Stoppe, MD    0049-024108036575    cstoppe@ukaachen.de   
Principal Investigator: Christian Stoppe, MD         
Klinik und Poliklinik für Anästhesiologie und Operative Intensivmedizin Universitätsklinikum Bonn Recruiting
Bonn, Germany
Contact: Maria Wittman, MD         
Universitätsklinikum Frankfurt Recruiting
Frankfurt, Germany, 60590
Contact: Patrick Meybohm, MD    : 069/ 6301 - 5998    patrick.meybohm@kgu.de   
Principal Investigator: Patrick Meybohm, MD         
Klinik für Her- und Gefäßchirurgie Universitäts-Herzzentrum Freiburg Recruiting
Freiburg, Germany
Contact: Georg Trummer, MD         
Klinik für Herz-, Kinderherz- und Gefäßchirurgie UKGM Giessen Recruiting
Gießen, Germany
Contact: Bernd Niemann, MD         
University Medical Center Schleswig-Holstein Recruiting
Kiel, Germany
Contact: Gunnar Elke, MD    +49 431 5972991    gunnar.elke@uksh.de   
Klinik und Poliklinik für Herz- und Thoraxchirurgie Uniklinik Köln Recruiting
Koln, Germany
Contact: Oliver Liakopoulos, MD         
Klinik für Anästhesiologie Universitätsmedizin Mainz Recruiting
Mainz, Germany
Contact: Rita Laufenberg, MD         
Klinik für Anästhesiologie Klinikum der Universität München Recruiting
München, Germany
Contact: Erich Kilger, MD         
Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie Universitätsmedizin Münster, Zentralklinikum Recruiting
Münster, Germany
Contact: Thomas Ermert, MD         
Klinikum Oldenburg gGmbH Universitätsklinik für Anästhesiologie / Intensivmedizin / Notfallmedizin / Schmerztherapie Recruiting
Oldenburg, Germany
Contact: Malte Book, MD         
Contact: Thomas Grote, MD         
Klinik und Poliklinik für Anästhesiologie und Intensivtherapie Universitätsmedizin Rostock Not yet recruiting
Rostock, Germany
Contact: Frank Kletzin         
Sponsors and Collaborators
Daren K. Heyland
biosyn Arzneimittel GmbH
Queen's University
RWTH Aachen University
Investigators
Principal Investigator: Daren K Heyland, MD Queen's University
Principal Investigator: Christian Stoppe, MD RWTH Aachen University Hospital
Principal Investigator: Bernard J McDonald, MD Ottawa Heart Institute Research Corporation
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Daren K. Heyland, Scientific Director, Clinical Evaluation Research Unit at Kingston General Hospital
ClinicalTrials.gov Identifier: NCT02002247     History of Changes
Other Study ID Numbers: SUSTAIN CSX
First Submitted: November 28, 2013
First Posted: December 5, 2013
Last Update Posted: October 3, 2017
Last Verified: October 2017

Keywords provided by Daren K. Heyland, Clinical Evaluation Research Unit at Kingston General Hospital:
antioxidants
selenium
heart disease
cardiac surgery
perioperative

Additional relevant MeSH terms:
Heart Diseases
Sodium Selenite
Cardiovascular Diseases
Selenium
Selenious Acid
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Trace Elements
Micronutrients
Growth Substances